Brief summary of my research:
Frank Staal was trained in biomedicine at the Faculty of Medicine of Utrecht University, the Netherlands. He obtained both his Bachelor and Master degrees cum laude from this university and then moved to Stanford University, CA USA, for his PhD degree in Genetics under supervision of the late Leonard Herzenberg and his wife Leonore Herzenberg . His thesis work involved fundamental and translational aspects of HIV disease. His first postdoctoral work focused on human T cell development, which he extended to genetic mouse models in his second postdoctoral period as fellow of the Dutch Royal Academy of Sciences under guidance of Hans Clevers, where he started to work on Wnt signalling. He was recruited by Erasmus Medical School in 2000 to start his own lab focusing on mouse and human T cell development. During this period at ErasmusMC, Rotterdam, he got interested in gene therapy for SCID, a disease in babies in which T cell development is blocked due to inherited mutations in key developmental genes. In 2007 he was appointed full professor at Leiden University Medical School and moved his lab from Rotterdam to Leiden. He is currently focusing on clinical implementation of gene therapy for RAG-SCID, other gene therapy approaches with blood stem cells and basic stem and T cell biology. Fittingly, his appointment is in the Department of Immunohematology, where the late Jon van Rood performed the first bone marrow transplantation for SCID exactly 50 years ago.
Period Institution Degree Field
1984-1985 Utrecht University, Netherlands B.Sc.(cum laude) Med. Biology
1985-1989 Utrecht University, Netherlands M.Sc.(cum laude) Med. Biology
1989-1993 Stanford University, U.S.A. Ph.D. Genetics
Functional definition of a transcription factor hierarchy regulating T cell lineage commitment.
Garcia-Perez L, Famili F, Cordes M, Brugman M, van Eggermond M, Wu H, Chouaref J, Granado DSL, Tiemessen MM, Pike-Overzet K, Daxinger L, Staal FJT.
Sci Adv. 2020 Jul 31;6(31):eaaw7313. doi: 10.1126/sciadv.aaw7313.
Successful Preclinical Development of Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID.
Garcia-Perez L, van Eggermond M, van Roon L, Vloemans SA, Cordes M, Schambach A, et al.
Mol Ther Methods Clin Dev. 2020 Mar 31;17:666-682. doi: 10.1016/j.omtm.2020.03.016.
Autologous Stem-Cell-Based Gene Therapy for Inherited Disorders: State of the Art and Perspectives.
Staal FJT, Aiuti A, Cavazzana M.
Front Pediatr. 2019 Oct 31;7:443. doi: 10.3389/fped.2019.00443. eCollection 2019.PMID